Vivus previously announced pricing for Qsymia — ranging from $4-6 per day depending on the dosage strength — that was in line with investor expectations.
Qsymia combines two drugs, phentermine and topiramate, that are available as generics for a combined price of around $1 to $3 per day. Will doctors choose to prescribe Qsymia to their obese patients or recommend the individual, generic components? Investors have been debating the question leading up to the drug's launch.
"Feedback from doctors indicates that generic substitution is unlikely to be widespread given the associated liability of either prescribing or dispensing the generic components separately so long as the product [Qsymia] is not made too cost prohibitive," said J.P. Morgan biotech analyst Cory Kasimov in a recent research report.
But in August, Jefferies analyst Thomas Wei downgraded Vivus, citing concerns that doctors will choose to prescribe the generic components of Qsymia instead of the branded (and higher priced) product.
With Qsymia now available in the U.S., investors and analysts will be watching daily and weekly prescription sales tracked by independent services like IMS Health and Wolters Kluwer.
Vivus shares were unchanged at $22.08 in early Monday trading. Arena shares were up 6 cents to $8.41. Both stocks have fallen since their respective weight-loss drugs were approved earlier this summer, reflecting investor uncertainty about the commercial potential of obesity drugs.
—By TheStreet.com’s Adam Feuerstein
Additional News: Weight-Loss Pill Fattens Arena Shares
Additional Views: Despite Backlash, Cramer Remains Skeptical of Arena
CNBC Data Pages:
TheStreet’s editorial policy prohibits staff editors, reporters, and analysts from holding positions in any individual stocks.